Simulations Plus, Inc. (Nasdaq: SLP), a key player in model-informed and AI-accelerated drug development globally, has addressed the recent draft guidance from the U.S. Food and Drug Administration (FDA) regarding streamlined nonclinical safety studies for monospecific monoclonal antibodies. This guidance aims to decrease dependence on animal trials and enhance mechanistic comprehension and pharmacokinetic understanding. Simulations Plus, known for its innovations in biopharma, is responding to this initiative, emphasizing a shift towards advanced approaches in drug development.